Linagliptin Viatris

Linagliptin, the active ingredient in Linagliptin Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus.

GNH USA supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor indicated for managing type 2 diabetes mellitus.

- Type 2 diabetes mellitus (monotherapy): improves glycemic control when used alone. - Type 2 diabetes mellitus (combination therapy): enhances glucose lowering when added to metformin or other oral agents. - Type 2 diabetes mellitus (adjunct to diet and exercise): helps achieve target HbA1c as part of comprehensive management.

Linagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nose and throat. - Headache: transient cranial pain. - Upper respiratory tract infection: symptoms of cough, sore throat, or congestion. - Dizziness: brief episodes of light‑headedness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder.

Before initiating Linagliptin therapy, certain clinical considerations should be reviewed.

- Renal impairment: dose adjustment is not required, but monitor renal function regularly. - Hepatic impairment: use with caution in patients with moderate liver disease. - Cardiovascular disease: assess risk as patients with heart failure may need closer observation. - Elderly patients: start at the recommended dose and monitor for adverse effects. - Concomitant medications: review for potential interactions, especially with insulin or sulfonylureas. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Linagliptin can affect or be affected by other medicines; interactions are classified by clinical significance.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia; dose of the co‑administered agent may need reduction. - Strong CYP3A4 inhibitors: may raise linagliptin plasma levels, requiring careful monitoring.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce linagliptin exposure, potentially decreasing efficacy. - Diuretics: may enhance the glucose‑lowering effect, necessitating glucose monitoring. - Anticoagulants (e.g., warfarin): monitor INR as occasional alterations have been reported.